Drugs / LM-101
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05615974 | Jan 2023 → Jan 2027 expected | cancer | LaNova Medicines Limited | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LM-101 | “LM-101, an Anti-SIRPα Antibody” PMID 41910591 ↗ Jun 2026 |
| Action | Inhibit | “blocks the CD47-SIRPα interaction” PMID 41910591 ↗ Jun 2026 |
| Route | Intravenous | “Administered intravenously” NCT05615974 ↗ |
| Target | SIRPA | “blocks the CD47-SIRPα interaction” PMID 41910591 ↗ Jun 2026 |